NASDAQ : VRAX
Virax Biolabs Group Limited — Financial statements
Healthcare · Biotechnology · United Kingdom
Last price 1.21 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 964.36K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Virax Biolabs Group Limited (VRAX) reported revenue of 12.42K USD (TTM). Five years of income statement, balance sheet, cash flow and ratios below.
Income statement
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Revenue | 12.42K | 12.42K | 6.33K | 156.42K | 8.56K | |
| Cost of Revenue | 4.73K | 4.73K | 59.40K | 105.83K | 9.93K | |
| Gross Profit | 7.69K | 7.69K | -53.07K | 50.59K | -1.36K | |
| Selling, General & Admin | 2.67M | 2.67M | 3.99M | 4.57M | 3.55M | 1.30M |
| Research & Development | 3.74M | 3.74M | 2.03M | 1.61M | 2.18M | 433.74K |
| Operating Expenses | 6.41M | 6.41M | 6.02M | 6.19M | 5.73M | 1.73M |
| Operating Income | -6.40M | -6.40M | -6.08M | -6.14M | -5.73M | -1.73M |
| Interest Expense | -61.77K | -61.77K | -58.18K | -26.88K | -15.47K | -15.44K |
| Currency Exchange Gain (Loss) | 529.04K | 529.04K | -86.09K | 29.21K | ||
| Other Non Operating Income (Expenses) | 33.00 | 33.00 | 17.18K | -17.73K | -3.92K | -753.00 |
| EBT Excluding Unusual Items | -5.93M | -5.93M | -6.20M | -6.15M | -5.75M | -1.75M |
| Asset Writedown | -390.36K | |||||
| Legal Settlements | -210.50K | |||||
| Other Unusual Items | 12.46K | 294.38K | ||||
| Pretax Income | -5.93M | -5.93M | -6.20M | -6.74M | -5.46M | -1.75M |
| Income Tax Expense | -900.24K | -900.24K | -136.66K | |||
| Earnings From Continuing Operations | -5.03M | -5.03M | -6.07M | -6.74M | -5.46M | -1.75M |
| Minority Interest in Earnings | 8.43K | 8.43K | 5.99K | 5.58K | 269.00 | 41.04K |
| Net Income | -5.02M | -5.02M | -6.06M | -6.73M | -5.46M | -1.71M |
| Net Income to Common | -5.02M | -5.02M | -6.06M | -6.73M | -5.46M | -1.71M |
| Shares Outstanding (Basic) | 397.59K | 397.59K | 149.21K | 80.26K | 42.52K | 38.25K |
| Shares Outstanding (Diluted) | 397.59K | 397.59K | 149.21K | 80.26K | 42.52K | 38.25K |
| EPS (Basic) | -12.64 | -12.64 | -40.62 | -83.90 | -128.35 | -44.67 |
| EPS (Diluted) | -12.64 | -12.64 | -40.62 | -83.90 | -128.35 | -44.75 |
| Free Cash Flow | -4.88M | -4.88M | -5.17M | -7.35M | -4.18M | -809.07K |
| Free Cash Flow Per Share | -12.27 | -12.27 | -34.63 | -91.57 | -98.30 | -21.15 |
| Gross Margin | 61.90% | 61.90% | 32.34% | -15.94% | ||
| Operating Margin | -51,515.17% | -51,515.17% | -95,984.87% | -3,922.37% | -66,963.68% | |
| Profit Margin | -40,439.11% | -40,439.11% | -95,739.17% | -4,304.81% | -63,748.32% | |
| Free Cash Flow Margin | -39,263.65% | -39,263.65% | -81,621.64% | -4,698.55% | -48,823.35% | |
| EBITDA | -6.05M | -6.05M | -5.82M | -6.08M | ||
| D&A For EBITDA | 351.58K | 351.58K | 256.69K | 54.87K | ||
| EBIT | -6.40M | -6.40M | -6.08M | -6.14M | -5.73M | -1.73M |
Balance sheet
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 6.44M | 6.44M | 4.23M | 3.59M | 9.35M | 21.76K |
| Short-Term Investments | 79.30K | 79.30K | 94.19K | 77.32K | 49.26K | 6.00K |
| Cash & Short-Term Investments | 6.52M | 6.52M | 4.32M | 3.67M | 9.40M | 27.75K |
| Other Receivables | 27.11K | 27.11K | 30.65K | 217.84K | ||
| Receivables | 27.11K | 27.11K | 30.65K | 217.84K | ||
| Inventory | 48.04K | 48.04K | 188.74K | 184.39K | 24.09K | 20.95K |
| Prepaid Expenses | 235.24K | 235.24K | 351.13K | 311.45K | 208.12K | |
| Total Current Assets | 6.83M | 6.83M | 4.89M | 4.38M | 9.63M | 48.71K |
| Property, Plant & Equipment | 1.50M | 1.50M | 1.49M | 1.05M | ||
| Other Intangible Assets | 39.65K | 49.77K | 178.40K | |||
| Total Assets | 8.32M | 8.32M | 6.43M | 5.48M | 9.81M | 48.71K |
| Accounts Payable | 51.77K | 51.77K | 56.09K | 45.63K | 159.91K | 846.47K |
| Accrued Expenses | 523.68K | 523.68K | 531.65K | 75.26K | 545.70K | 395.18K |
| Short-Term Debt | 28.48K | 28.48K | 32.47K | 164.55K | ||
| Current Portion of Leases | 81.10K | 81.10K | 52.99K | 47.95K | ||
| Current Unearned Revenue | 38.25K | |||||
| Other Current Liabilities | 3.76K | |||||
| Total Current Liabilities | 685.02K | 685.02K | 673.21K | 168.85K | 908.40K | 1.25M |
| Long-Term Leases | 304.81K | 304.81K | 291.54K | 176.34K | ||
| Total Liabilities | 989.83K | 989.83K | 964.75K | 345.19K | 908.40K | 1.25M |
| Common Stock | 14.48K | 14.48K | 4.34K | 2.57K | 1.56K | 999.00 |
| Retained Earnings | -29.61M | -29.61M | -24.59M | -18.53M | -11.79M | -6.34M |
| Comprehensive Income & Other | 37.18M | 37.18M | 30.28M | 23.89M | 20.92M | 5.36M |
| Total Common Equity | 7.58M | 7.58M | 5.70M | 5.37M | 9.13M | -974.58K |
| Minority Interest | -242.40K | -242.40K | -233.97K | -227.98K | -222.40K | -222.13K |
| Shareholders' Equity | 7.33M | 7.33M | 5.46M | 5.14M | 8.90M | -1.20M |
| Total Liabilities & Equity | 8.32M | 8.32M | 6.43M | 5.48M | 9.81M | 48.71K |
| Total Debt | 414.39K | 414.39K | 377.00K | 224.30K | 164.55K | |
| Net Cash (Debt) | 6.10M | 6.10M | 3.95M | 3.44M | 9.24M | 27.75K |
| Net Cash Per Share | 15.35 | 15.35 | 26.45 | 42.89 | 217.25 | 0.73 |
| Filing Date Shares Outstanding | 579.22K | 579.22K | 173.68K | 102.96K | 71.56K | 39.91K |
| Total Common Shares Outstanding | 579.22K | 579.22K | 173.68K | 102.96K | 62.19K | 39.91K |
| Working Capital | 6.14M | 6.14M | 4.22M | 4.21M | 8.73M | -1.20M |
| Book Value Per Share | 13.08 | 13.08 | 32.80 | 52.13 | 146.76 | -24.42 |
| Tangible Book Value | 7.58M | 7.58M | 5.66M | 5.32M | 8.95M | -974.58K |
| Tangible Book Value Per Share | 13.08 | 13.08 | 32.57 | 51.64 | 143.89 | -24.42 |
| Machinery | 1.85M | 1.85M | 1.49M | 902.73K | 11.10K |
Cash flow statement
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Net Income | -5.02M | -5.02M | -6.06M | -6.73M | -5.46M | -1.71M |
| Depreciation & Amortization | 429.37K | 429.37K | 333.47K | 103.10K | ||
| Other Amortization | 9.65K | 9.65K | 9.91K | |||
| Loss (Gain) From Sale of Assets | 32.19K | 32.19K | ||||
| Asset Writedown & Restructuring Costs | 390.36K | |||||
| Stock-Based Compensation | 130.41K | 130.41K | 365.31K | 1.01M | 1.75M | 290.36K |
| Other Operating Activities | -458.49K | -458.49K | 163.36K | 101.12K | -294.54K | -35.00K |
| Change in Accounts Receivable | 928.00 | |||||
| Change in Inventory | 94.67K | 94.67K | -34.29K | -60.38K | 20.95K | 121.00 |
| Change in Accounts Payable | -12.30K | -12.30K | 466.85K | -572.25K | 33.94K | 641.16K |
| Change in Unearned Revenue | -38.25K | 38.25K | ||||
| Change in Other Net Operating Assets | 176.36K | 176.36K | 193.06K | -599.06K | -275.48K | 2.19K |
| Operating Cash Flow | -4.62M | -4.62M | -4.56M | -6.40M | -4.18M | -809.07K |
| Capital Expenditures | -255.83K | -255.83K | -603.89K | -952.50K | ||
| Sale (Purchase) of Intangibles | -211.95K | -178.40K | ||||
| Investing Cash Flow | -255.83K | -255.83K | -603.89K | -1.16M | -178.40K | |
| Short-Term Debt Issued | 4.41M | 4.41M | 487.50K | 293.59K | ||
| Total Debt Issued | 4.41M | 4.41M | 487.50K | 293.59K | ||
| Short-Term Debt Repaid | -18.30K | -452.89K | ||||
| Long-Term Debt Repaid | -109.48K | -109.48K | -107.76K | -56.37K | ||
| Lease Payments | -109.48K | -109.48K | -107.76K | -56.37K | ||
| Total Debt Repaid | -109.48K | -109.48K | -107.76K | -74.66K | -452.89K | |
| Net Debt Issued (Repaid) | 4.30M | 4.30M | -107.76K | -74.66K | 34.60K | 293.59K |
| Issuance of Common Stock | 2.78M | 2.78M | 5.91M | 1.87M | 13.65M | 519.61K |
| Financing Cash Flow | 7.09M | 7.09M | 5.81M | 1.80M | 13.69M | 813.21K |
| Net Cash Flow | 2.21M | 2.21M | 639.70K | -5.76M | 9.33M | 4.13K |
| Free Cash Flow | -4.88M | -4.88M | -5.17M | -7.35M | -4.18M | -809.07K |
| Free Cash Flow Margin | -39,263.65% | -39,263.65% | -81,621.64% | -4,698.55% | -48,823.35% | |
| Free Cash Flow Per Share | -12.27 | -12.27 | -34.63 | -91.57 | -98.30 | -21.15 |
| Levered Free Cash Flow | -3.48M | -3.48M | -2.85M | -4.81M | -2.73M | -252.08K |
| Unlevered Free Cash Flow | -3.44M | -3.44M | -2.82M | -4.79M | -2.72M | -242.44K |
| Free Cash Flow After Leases | -4.99M | -4.99M | -5.28M | -7.41M | -4.18M | -809.07K |
| Change in Working Capital | 258.73K | 258.73K | 625.62K | -1.27M | -182.33K | 644.39K |
Ratios
Fiscal year April - March; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 964.36K | 1.63M | 4.95M | 1.69M | 10.81M | |
| Enterprise Value | -5.14M | -1.51M | -2.06M | -3.56M | 6.00M | |
| Last Close Price | 1.21 | 5.50 | 28.50 | 17.93 | 173.85 | |
| PS Ratio | 77.63 | 131.40 | 781.84 | 10.83 | 1,262.87 | |
| PB Ratio | 0.09 | 0.22 | 0.91 | 0.33 | 1.21 | |
| P/TBV Ratio | 0.13 | 0.21 | 0.88 | 0.32 | 1.21 | |
| EV/Sales Ratio | 701.38 | |||||
| Debt / Equity Ratio | 0.06 | 0.06 | 0.07 | 0.04 | 0.02 | |
| Net Debt / Equity Ratio | -0.83 | -0.83 | -0.72 | -0.67 | -1.04 | 0.02 |
| Net Debt / EBITDA Ratio | 1.01 | 1.01 | 0.68 | 0.57 | ||
| Net Debt / FCF Ratio | 1.25 | 1.25 | 0.76 | 0.47 | 2.21 | 0.03 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | |
| Inventory Turnover | 0.04 | 0.04 | 0.32 | 1.01 | 0.44 | |
| Quick Ratio | 9.55 | 9.55 | 6.47 | 23.00 | 10.35 | 0.02 |
| Current Ratio | 9.97 | 9.97 | 7.27 | 25.94 | 10.61 | 0.04 |
| Return on Equity (ROE) | -78.65% | -78.65% | -114.47% | -95.98% | -141.63% | |
| Return on Assets (ROA) | -54.23% | -54.23% | -63.77% | -50.14% | -72.67% | -2,453.52% |
| Return on Capital Employed (ROCE) | -83.80% | -83.80% | -105.60% | -115.40% | -64.40% | 144.90% |
| Earnings Yield | -1,044.63% | -307.75% | -122.45% | -397.62% | -50.48% | |
| FCF Yield | -505.80% | -298.81% | -104.40% | -433.98% | -38.66% | |
| Buyback Yield / Dilution | -166.46% | -166.46% | -85.92% | -88.76% | -11.15% |